Sep 2026
Circulating fibroblast growth factor 21 predicts adverse outcomes in patients with pre-heart failure and HFpEF.
Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of patients with heart failure. Given its complex pathogenesis, non-invasive biomarkers are urgently needed. Fibroblast growth factor 21 (FGF21) modulates metabolism and inflammation, yet its prognostic role in the development and progre...
Hui-Ying Li, Yu Bao, Hu-Nan Xiao et al.
· Pathology, Research and Prac... · 0 citations